https://scholars.lib.ntu.edu.tw/handle/123456789/635776
Title: | Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301 | Authors: | Cho, Byoung Chul Ahn, Myung-Ju Kang, Jin Hyoung Soo, Ross A Reungwetwattana, Thanyanan CHIH-HSIN YANG Cicin, Irfan Kim, Dong-Wan Wu, Yi-Long Lu, Shun Lee, Ki Hyeong Pang, Yong-Kek Zimina, Anastasia Fong, Chin Heng Poddubskaya, Elena Sezer, Ahmet How, Soon Hin Danchaivijitr, Pongwut Kim, YuKyung Lim, Yeji An, Taewon Lee, Hana Byun, Hae Mi Zaric, Bojan |
Issue Date: | 10-Sep-2023 | Journal Volume: | 41 | Journal Issue: | 26 | Source: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | Abstract: | Lazertinib is a potent, CNS-penetrant, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This global, phase III study (LASER301) compared lazertinib versus gefitinib in treatment-naïve patients with EGFR-mutated (exon 19 deletion [ex19del]/L858R) locally advanced or metastatic non-small-cell lung cancer (NSCLC). |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/635776 | ISSN: | 0732-183X 1527-7755 |
DOI: | 10.1200/JCO.23.00515 |
Appears in Collections: | 腫瘤醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.